{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:14:38Z","timestamp":1768738478235,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Gerontology and Geriatrics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.archger.2020.104091","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T16:07:13Z","timestamp":1588608433000},"page":"104091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Efficacy and safety of valproic acid in dementia: A systematic review with meta-analysis"],"prefix":"10.1016","volume":"89","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.archger.2020.104091_bib0005","article-title":"Valproic preparations for agitation in dementia","volume":"10","author":"Baillon","year":"2018","journal-title":". Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.archger.2020.104091_bib0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1474-4422(09)70240-6","article-title":"Epilepsy in later life","volume":"8","author":"Brodie","year":"2009","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.archger.2020.104091_bib0015","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.archger.2020.104091_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000097757","article-title":"A placebo-controlled trial of valproic for agitation and aggression in Alzheimer\u2019s disease","volume":"23","author":"Herrmann","year":"2007","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1016\/j.archger.2020.104091_bib0025","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"key":"10.1016\/j.archger.2020.104091_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/(SICI)1099-1166(199801)13:1<29::AID-GPS726>3.0.CO;2-Z","article-title":"The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances","volume":"13","author":"Kunik","year":"1998","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.archger.2020.104091_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40263-013-0124-4","article-title":"Mitochondrial enhancement for neurodegenerative movement disorders: A systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone","volume":"28","author":"Liu","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.archger.2020.104091_bib0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/10717544.2017.1413446","article-title":"The efficacy and safety of riluzole for neurodegenerative movement disorders: A systematic review with meta-analysis","volume":"25","author":"Liu","year":"2018","journal-title":"Drug Delivery"},{"key":"10.1016\/j.archger.2020.104091_bib0045","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.0b013e3182a4a3cb","article-title":"Dementia in China: Current status","volume":"81","author":"Liu","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.archger.2020.104091_bib0050","article-title":"Treatment of epilepsy for people with Alzheimer\u2019s disease","volume":"11","author":"Liu","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.archger.2020.104091_bib0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1567205011310030005","article-title":"Valproic acid attenuates neuronal loss in the brain of APP\/PS1 double transgenic Alzheimer\u2019s disease mice model","volume":"10","author":"Long","year":"2013","journal-title":"Current Alzheimer Research"},{"key":"10.1016\/j.archger.2020.104091_bib0060","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1176\/jnp.7.3.314","article-title":"Valproic in the treatment of behavioral agitation in elderly patients with dementia","volume":"7","author":"Lott","year":"1995","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.archger.2020.104091_bib0065","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.neurobiolaging.2007.04.004","article-title":"Proteomic analysis of peripheral leukocytes in Alzheimer\u2019s disease patients treated with divalproex sodium","volume":"29","author":"Mhyre","year":"2008","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.archger.2020.104091_bib0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5698\/1535-7511-12.5.184","article-title":"Seizures in Alzheimer disease: Clinical and epidemiological data","volume":"12","author":"Pandis","year":"2012","journal-title":"Epilepsy Currents"},{"key":"10.1016\/j.archger.2020.104091_bib0075","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1517\/14712598.2014.935332","article-title":"Amyloid-directed monoclonal antibodies for the treatment of Alzheimer\u2019s disease: The point of no return?","volume":"14","author":"Panza","year":"2014","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.archger.2020.104091_bib0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00019442-200102000-00009","article-title":"Placebo-controlled study of divalproex sodium for agitation in dementia","volume":"9","author":"Porsteinsson","year":"2001","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.archger.2020.104091_bib0085","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/156720505774932205","article-title":"A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer\u2019s disease","volume":"2","author":"Profenno","year":"2005","journal-title":"Current Alzheimer Research"},{"key":"10.1016\/j.archger.2020.104091_bib0090","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1742-1241.2001.tb11087.x","article-title":"Age of seizure onset in adults with Down\u2019s syndrome","volume":"55","author":"Puri","year":"2001","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.archger.2020.104091_bib0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","article-title":"The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia","volume":"173","author":"Reus","year":"2016","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.archger.2020.104091_bib0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/gps.653","article-title":"Sodium valproic in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial","volume":"17","author":"Sival","year":"2002","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.archger.2020.104091_bib0105","first-page":"942","article-title":"Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: A randomized, controlled trial","volume":"13","author":"Tariot","year":"2005","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.archger.2020.104091_bib0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.archger.2020.104091_bib0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0011-393X(01)80042-4","article-title":"Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial","volume":"62","author":"Tariot","year":"2001","journal-title":"Current Therapeutic Research"},{"key":"10.1016\/j.archger.2020.104091_bib0120","first-page":"157","article-title":"Seizure susceptibility and mortality in mice that over-express amyloid precursor protein","volume":"1","author":"Westmark","year":"2008","journal-title":"International Journal of Clinical and Experimental Pathology"}],"container-title":["Archives of Gerontology and Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167494320300856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167494320300856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:06:35Z","timestamp":1759089995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167494320300856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":24,"alternative-id":["S0167494320300856"],"URL":"https:\/\/doi.org\/10.1016\/j.archger.2020.104091","relation":{},"ISSN":["0167-4943"],"issn-type":[{"value":"0167-4943","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of valproic acid in dementia: A systematic review with meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Archives of Gerontology and Geriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.archger.2020.104091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104091"}}